Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria. 2016

Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
Institute for Disease Modeling, Intellectual Ventures Laboratory, Bellevue, Washington, USA mfamulare@intven.com.

To assess the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular evolution in Sabin-like poliovirus isolates from Nigerian acute flaccid paralysis cases obtained from routine surveillance. We employed a novel modeling approach to infer substitution and recombination rates from whole-genome sequences and information about poliovirus infection dynamics and the individual vaccination history. We confirmed observations from a recent vaccine trial that VP1 substitution rates are increased for Sabin-like isolates relative to the rate for the wild type due to increased nonsynonymous substitution rates. We also inferred substitution rates for attenuating nucleotides and confirmed that reversion can occur in days to weeks after vaccination. We combine our observations for Sabin-like virus evolution with the molecular clock for VP1 of circulating wild-type strains to infer that the mean time from the initiating vaccine dose to the earliest detection of circulating vaccine-derived poliovirus (cVDPV) is 300 days for Sabin-like virus type 1, 210 days for Sabin-like virus type 2, and 390 days for Sabin-like virus type 3. Phylogenetic relationships indicated transient local transmission of Sabin-like virus type 3 and, possibly, Sabin-like virus type 1 during periods of low wild polio incidence. Comparison of Sabin-like virus recombinants with known Nigerian vaccine-derived poliovirus recombinants shows that while recombination with non-Sabin enteroviruses is associated with cVDPV, the recombination rates are similar for Sabin isolate-Sabin isolate and Sabin isolate-non-Sabin enterovirus recombination after accounting for the time from dosing to the time of detection. Our study provides a comprehensive picture of the evolutionary dynamics of the oral polio vaccine in the field. OBJECTIVE The global polio eradication effort has completed its 26th year. Despite success in eliminating wild poliovirus from most of the world, polio persists in populations where logistical, social, and political factors have not allowed vaccination programs of sustained high quality. One issue of critical importance is eliminating circulating vaccine-derived polioviruses (cVDPVs) that have properties indistinguishable from those of wild poliovirus and can cause paralytic disease. cVDPV emerges due to the genetic instability of the Sabin viruses used in the oral polio vaccine (OPV) in populations that have low levels of immunity to poliovirus. However, the dynamics responsible are incompletely understood because it has historically been difficult to gather and interpret data about evolution of the Sabin viruses used in OPV in regions where cVDPV has occurred. This study is the first to combine whole-genome sequencing of poliovirus isolates collected during routine surveillance with knowledge about the intrahost dynamics of poliovirus to provide quantitative insight into polio vaccine evolution in the field.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D009549 Nigeria A republic in western Africa, south of NIGER between BENIN and CAMEROON. Its capital is Abuja. Federal Republic of Nigeria
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D011051 Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) Infantile Paralysis,Polio,Poliomyelitis, Nonpoliovirus,Poliomyelitis, Preparalytic,Encephalitis, Polio,Epidemic Acute Poliomyelitis,Polio Encephalitis,Poliomyelitis Infection,Poliomyelitis, Acute,Acute Poliomyelitis,Acute Poliomyelitis, Epidemic,Infection, Poliomyelitis,Infections, Poliomyelitis,Nonpoliovirus Poliomyelitis,Paralysis, Infantile,Poliomyelitides, Preparalytic,Poliomyelitis Infections,Poliomyelitis, Epidemic Acute,Polios,Preparalytic Poliomyelitis
D011055 Poliovirus Vaccine, Oral A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed) Sabin Vaccine,Oral Poliovirus Vaccine,Vaccine, Oral Poliovirus,Vaccine, Sabin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females

Related Publications

Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 1993, Developments in biological standardization,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
October 1984, Nucleic acids research,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 1961, Boletin medico del Hospital Infantil de Mexico,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 1962, Indian journal of medical sciences,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 2006, Acta virologica,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
June 2017, Virusdisease,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
June 2011, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 2015, Trials in vaccinology,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
May 1973, Bulletin of the World Health Organization,
Michael Famulare, and Stewart Chang, and Jane Iber, and Kun Zhao, and Johnson A Adeniji, and David Bukbuk, and Marycelin Baba, and Matthew Behrend, and Cara C Burns, and M Steven Oberste
January 1987, Acta Leidensia,
Copied contents to your clipboard!